Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 19, 2020
Reporting Period: Single event date (May 19, 2020)
Business Context: The Company is an emerging growth company focused on cellular therapy. This filing reports the publication of a scientific review article authored by the Company's Chief Scientific Officer.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
There are no material financial changes reported in this filing. The material event is the publication of a review article titled "Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer" in the journal Stem Cells Translational Medicine. The article was co-authored by May Sabry, PhD, and Mark Lowdell, PhD (Co-founder and CSO of Inmune Bio).
Guidance, Outlook, and Risks
Management Commentary: The filing serves to disseminate the press release regarding the scientific publication. No financial guidance or operational outlook is provided in this document.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the information is furnished and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It explicitly states that the information shall not be incorporated by reference into other registration statements unless expressly set forth by specific reference.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the scientific findings.
- Confirm the credentials and current roles of the authors (May Sabry, PhD and Mark Lowdell, PhD) as described in the filing.
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.
- Note that this document is an "Other Event" (Item 8.01) and does not represent a change in financial status or corporate structure.